
Christos J Markopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4824144/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, The, 2015, 386, 1341-1352.	13.7	1,072
2	Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. New England Journal of Medicine, 2006, 354, 709-718.	27.0	593
3	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, The, 2015, 386, 1353-1361.	13.7	581
4	Adiponectin and Breast Cancer Risk. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1102-1107.	3.6	488
5	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet, The, 2011, 377, 321-331.	13.7	346
6	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 590-7.	7.4	182
7	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 2016, 27, 379-390.	1.2	165
8	Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 2011, 29, 1531-1538.	1.6	160
9	Impact of Breast Cancer Surgery on the Self-Esteem and Sexual Life of Female Patients. Journal of International Medical Research, 2009, 37, 182-188.	1.0	124
10	Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes and Control, 2000, 11, 383-388.	1.8	115
11	Heterogeneous <i>HER2</i> Gene Amplification. American Journal of Clinical Pathology, 2011, 136, 266-274.	0.7	101
12	Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study. Journal of Clinical Oncology, 2014, 32, 2951-2958.	1.6	101
13	The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Research and Treatment, 2016, 157, 281-294.	2.5	98
14	Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. BMJ: British Medical Journal, 1988, 296, 1349-1351.	2.3	95
15	Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2005, 16, 1762-1771.	1.2	95
16	Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. BMC Cancer, 2019, 19, 535.	2.6	77
17	Expression of alpha-thymosins in human tissues in normal and abnormal growth Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9504-9507.	7.1	71
18	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial Breast Cancer Research, 2010, 12, R24	5.0	70

#	Article	IF	CITATIONS
19	Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. Journal of Clinical Oncology, 2013, 31, 2257-2264.	1.6	64
20	The Effect of Exemestane on the Lipidemic Profile of Postmenopausal Early Breast Cancer Patients: Preliminary Results of the TEAM Greek Sub-study. Breast Cancer Research and Treatment, 2005, 93, 61-66.	2.5	63
21	Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2002, 13, 1737-1742.	1.2	59
22	Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. Journal of Clinical Oncology, 2012, 30, 4477-4484.	1.6	58
23	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	2.5	48
24	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of Oncology, 2008, 19, 853-860.	1.2	45
25	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1211-1220.	10.7	45
26	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study. Breast, 2014, 23, 393-399.	2.2	44
27	Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapy. Breast Cancer Research and Treatment, 2006, 96, 251-261.	2.5	42
28	Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Annals of Oncology, 2009, 20, 49-55.	1.2	39
29	Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2008, 107, 431-441.	2.5	38
30	Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. European Journal of Cancer, 2018, 99, 1-8.	2.8	38
31	High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas. Cancer, 2002, 94, 2454-2465.	4.1	37
32	BRCA2 gene mutations in Greek patients with familial breast cancer. Human Mutation, 2002, 19, 81-82.	2.5	35
33	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Research and Treatment, 2005, 92, 1-9.	2.5	35
34	Correlation of molecular human leukocyte antigen typing and outcome in highâ€risk melanoma patients receiving adjuvant interferon. Cancer, 2010, 116, 4326-4333.	4.1	35
35	Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer: AÂcomprehensive review of current data. European Journal of Surgical Oncology, 2018, 44, 5-14.	1.0	35
36	Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. Breast, 2003, 12, 172-178.	2.2	34

#	Article	IF	CITATIONS
37	Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?. European Journal of Surgical Oncology, 2017, 43, 909-920.	1.0	34
38	Older patients with breast cancer: is there bias in the treatment they receive?. Therapeutic Advances in Medical Oncology, 2012, 4, 321-327.	3.2	33
39	Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives of Pathology and Laboratory Medicine, 2016, 140, 66-74.	2.5	33
40	The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anti-Cancer Drugs, 2014, 25, 950-957.	1.4	32
41	A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer. Advances in Therapy, 2015, 32, 1237-1247.	2.9	32
42	Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research, 2009, 11, R35.	5.0	31
43	Overview of the use of OncotypeDX®as an additional treatment decision tool in early breast cancer. Expert Review of Anticancer Therapy, 2013, 13, 179-194.	2.4	31
44	Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anti-Cancer Drugs, 2005, 16, 879-883.	1.4	30
45	Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications, 2018, 9, 4746.	12.8	30
46	Use of artificial neural networks (computer analysis) in the diagnosis of microcalcifications on mammography. European Journal of Radiology, 2001, 39, 60-65.	2.6	29
47	Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. British Journal of Surgery, 2010, 97, 671-679.	0.3	28
48	Sex Hormones in Postmenopausal Women with Breast Cancer on Tamoxifen. Hormone Research, 1997, 47, 116-120.	1.8	27
49	Autoimmune thyroid disease in women with breast carcinoma. European Journal of Surgical Oncology, 2001, 27, 626-630.	1.0	27
50	Glycogen-rich clear cell carcinoma of the breast. World Journal of Surgical Oncology, 2008, 6, 44.	1.9	26
51	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 2014, 14, 515.	2.6	26
52	Metastatic Melanoma in the Gallbladder: Report of a Case. Surgery Today, 2003, 33, 135-137.	1.5	25
53	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. Journal of Translational Medicine, 2010, 8, 108.	4.4	25
54	Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Radiotherapy and Oncology, 2013, 108, 190-196.	0.6	25

#	Article	IF	CITATIONS
55	Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Annals of Oncology, 2006, 17, 1835-1841.	1.2	23
56	Does patient education work in breast cancer? Final results from the global CARIATIDE study. Future Oncology, 2015, 11, 205-217.	2.4	23
57	Elderly Postmenopausal Patients With Breast Cancer Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis. Oncologist, 2013, 18, 8-13.	3.7	21
58	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. PLoS ONE, 2018, 13, e0200302.	2.5	21
59	Multigene assays in early breast cancer: Insights from recent phase 3 studies. European Journal of Surgical Oncology, 2020, 46, 656-666.	1.0	20
60	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. Journal of Clinical Oncology, 2020, 38, 3273-3281.	1.6	20
61	Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 LowÂStatus for Breast Cancer. Journal of Molecular Diagnostics, 2022, 24, 775-783.	2.8	20
62	Full Dose Paclitaxel Plus Vinorelbine as Salvage Chemotherapy in Anthracycline-Resistant Advanced Breast Cancer: A Phase II Study. Journal of Chemotherapy, 2003, 15, 607-612.	1.5	19
63	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunology, Immunotherapy, 2020, 69, 1549-1564.	4.2	19
64	Application of back propagation to the diagnosis of breast lesions by fine needle aspiration. Breast, 1997, 6, 293-298.	2.2	17
65	Management of Nonpalpable, Mammographically Detectable Breast Lesions. World Journal of Surgery, 1999, 23, 434-438.	1.6	17
66	Breast arterial calcifications as an indicator of systemic vascular disease. Acta Radiologica, 2004, 45, 726-729.	1.1	17
67	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. Npj Breast Cancer, 2017, 3, 3.	5.2	17
68	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational Oncology, 2017, 10, 589-598.	3.7	17
69	Depressive symptomatology correlates with phantom breast syndrome in mastectomized women. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 165-170.	3.2	16
70	Inflammatory Myofibroblastic Tumor of the Breast. Case Reports in Surgery, 2015, 2015, 1-5.	0.4	16
71	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment, 2016, 158, 307-321.	2.5	16
72	White blood cell and platelet indices as prognostic markers in patients with invasive ductal breast carcinoma. Oncology Letters, 2016, 12, 1610-1614.	1.8	15

#	Article	IF	CITATIONS
73	Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. British Journal of Cancer, 2014, 111, 2242-2247.	6.4	14
74	Mitoxantrone Plus Vinorelbine in Pretreated Patients with Metastatic Breast Cancer. Journal of Chemotherapy, 2007, 19, 582-589.	1.5	13
75	Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of Al trials. Cancer and Metastasis Reviews, 2010, 29, 581-594.	5.9	13
76	Surgery for liver metastases from breast cancer. Future Oncology, 2015, 11, 1519-1530.	2.4	13
77	Changes of Chromosomes 1, 3, 6, and 11 in Metastatic Effusions Arising from Breast and Ovarian Cancer. Cancer Genetics and Cytogenetics, 1999, 110, 34-40.	1.0	12
78	p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. Cytopathology, 2001, 12, 197-202.	0.7	12
79	Theoretical and practical knowledge curriculum for European Breast Surgeons. European Journal of Surgical Oncology, 2020, 46, 717-736.	1.0	12
80	Duration of Tamoxifen Effect on Lipidemic Profile of Postmenopausal Breast Cancer Patients following Deprivation of Treatment. Oncology, 2006, 70, 301-305.	1.9	11
81	Clinical experience of using oncotype DX as an additional treatment decision tool in early breast cancer – A retrospective analysis from 5 Greek institutions. European Journal of Surgical Oncology, 2012, 38, 413-419.	1.0	11
82	Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center. Cancer Genetics, 2018, 220, 1-12.	0.4	11
83	Diagnosis and treatment of intracystic breast carcinomas. American Surgeon, 2002, 68, 783-6.	0.8	11
84	Metastatic Retroperitoneal and Mediastinal Fibrosis as First Sign of Recurrence of Breast Cancer. The European Journal of Surgery, 2001, 167, 715-718.	0.9	10
85	Paraffinomas of the breast or oleogranulomatous mastitis—a rare entity. Breast, 2006, 15, 540-543.	2.2	10
86	When and how to operate on thoracic and lumbar spine fractures?. European Journal of Orthopaedic Surgery and Traumatology, 2014, 24, 443-451.	1.4	10
87	Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals - correlation with clinicopathological data. Clinical Genetics, 2005, 67, 322-329.	2.0	9
88	Controversial issues in the management of older adults with early breast cancer. Journal of Geriatric Oncology, 2017, 8, 397-402.	1.0	9
89	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. Anticancer Research, 2017, 37, 2947-2957.	1.1	9

Adenosis Tumor of the Breast. Breast Journal, 2003, 9, 255-256.

1.0 8

#	Article	IF	CITATIONS
91	Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. Journal of the National Cancer Institute, 2018, 110, 616-627.	6.3	8
92	Expression of pS2 Protein and Estrogen and Progesterone Receptor Status in Breast Cancer. Acta Cytologica, 1997, 41, 713-716.	1.3	7
93	DNA ploidy and pS2 protein expression in breast cancer. Cytopathology, 1997, 8, 171-176.	0.7	7
94	Phantom breast syndrome: The effect of in situ breast carcinoma. Psychiatry Research, 2010, 179, 333-337.	3.3	7
95	Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Research, 2003, 23, 2917-23.	1.1	7
96	Primary Actinomycosis Of The Greater Omentum. Journal of Infection, 2001, 43, 159-160.	3.3	6
97	Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. British Journal of Cancer, 2013, 109, 2453-2461.	6.4	6
98	Screening mammography: Usefulness beyond early detection of breast cancer. Atherosclerosis, 2016, 248, 1.	0.8	6
99	Clinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer. Cancer Genomics and Proteomics, 2021, 18, 285-294.	2.0	6
100	Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. World Journal of Clinical Oncology, 2014, 5, 374.	2.3	6
101	Pre-operative Tc-99m-Sestamibi Scanning and Intra-Operative Nuclear Mapping: Are they Accurate In Localizing Parathyroid Adenomas ?. Acta Chirurgica Belgica, 2003, 103, 626-630.	0.4	5
102	Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1569-1577.	2.5	5
103	Combination of Calcium Hydroxyapatite Antibiotic Carrier with Cement Spacers in Peri-Prosthetic Knee Infections. Surgical Infections, 2015, 16, 748-754.	1.4	5
104	Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches Journal of Clinical Oncology, 2012, 30, 517-517.	1.6	5
105	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. Cancer Genomics and Proteomics, 2022, 19, 60-78.	2.0	5
106	DNA content and p53 protein expression in ductal breast cancer. Cytopathology, 1997, 8, 322-327.	0.7	4
107	p53 Protein Expression in Benign and Malignant Breast Lesions. Acta Cytologica, 1998, 42, 918-922.	1.3	4
108	Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?. Annals of Oncology, 2005, 16, 1861-1866.	1.2	4

#	Article	IF	CITATIONS
109	Mitoxantrone Plus Gemcitabine in Pretreated Patients with Metastatic Breast Cancer. Journal of Chemotherapy, 2006, 18, 192-198.	1.5	4
110	Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients. Clinical Lipidology, 2010, 5, 245-254.	0.4	4
111	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2â^') breast cancer: When might multigene assays be of value?. Breast, 2017, 33, 191-199.	2.2	4
112	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. Breast Care, 2019, 14, 359-365.	1.4	4
113	Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?. Breast, 2013, 22, 488-494.	2.2	3
114	Breast cancer in the elderly: reducing the losses. Future Oncology, 2013, 9, 1253-1256.	2.4	3
115	A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon. PLoS ONE, 2014, 9, e86375.	2.5	3
116	Development of Early Malignant Bilateral Breast Disease in Relation to Antidepressant Treatment. Acta Chirurgica Belgica, 2005, 105, 660-661.	0.4	2
117	Aromatase inhibitors in the management of early breast cancer: The TEAM trial. European Journal of Surgical Oncology, 2009, 35, 333.	1.0	2
118	Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important. Breast Cancer Research, 2010, 12, 403.	5.0	2
119	Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons. Breast, 2016, 27, 27-34.	2.2	2
120	P5-16-02: The Impact of Educational Materials on Compliance and Persistence with Adjuvant Aromatase Inhibitors: 2 Year Follow-Up and Final Results from the CARIATIDE Study , 2011, , .		2
121	Computer-Assisted Navigation in Knee Surgery. Journal of Long-Term Effects of Medical Implants, 2012, 22, 313-322.	0.7	2
122	Fournier's gangrene: still highly lethal. Langenbecks Archiv Fur Chirurgie, 1997, 382, 15-18.	0.2	2
123	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. British Journal of Cancer, 2022, 127, 695-703.	6.4	2
124	DNA ploidy and vimentin expression in primary breast cancer. Cytopathology, 1995, 6, 325-330.	0.7	1
125	Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide. Clinical Drug Investigation, 2000, 19, 349-355.	2.2	1
126	Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor. Surgical Oncology, 2008, 17, 113-128.	1.6	1

#	Article	IF	CITATIONS
127	Are we treating the elderly with breast cancer to the same standard as younger patients?. Aging Health, 2012, 8, 1-3.	0.3	1
128	P247 A laboratory comparison of the 21-gene assay and PAM50-ROR. Breast, 2015, 24, S110-S111.	2.2	1
129	Complications of Breast Surgery and Their Management. , 2018, , 411-423.		1
130	Towards Harmonisation of Breast Care in Europe. Breast Care, 2019, 14, 341-343.	1.4	1
131	The challenge of avoiding over- and under-treatment in older women with ductal cancer in situ: A scoping review of existing knowledge gaps and a meta-analysis of real-world practice patterns. Journal of Geriatric Oncology, 2020, 11, 917-925.	1.0	1
132	High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas. Cancer, 2002, 94, 2454-2465.	4.1	1
133	Abstract P1-03-08: Different genomic rearrangements account for 17% ofBRCA1/2mutations in Greece. , 2015, , .		1
134	The role of Ki-67 in molecular breast cancer classification Journal of Clinical Oncology, 2012, 30, 583-583.	1.6	1
135	Abstract P4-11-10: Time dependence of biomarkers: Non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. , 2015, , .		1
136	Abstract P4-11-09: Comparison of immunohistochemical residual risk panels to predict risk in early breast cancers treated with endocrine therapy. , 2015, , .		1
137	Abstract S2-01: Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer. , 2015, , .		1
138	Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers Journal of Clinical Oncology, 2017, 35, 524-524.	1.6	1
139	Omitting chemotherapy in more patients with early breast cancer in the post-TAILORx era Journal of Clinical Oncology, 2020, 38, e12534-e12534.	1.6	1
140	TAMOXIFEN AND BREAST CANCER IN THE ELDERLY. Lancet, The, 1988, 331, 1218.	13.7	0
141	Bone mineral density in postmenopausal women with breast cancer and the effect of tamoxifen. Breast, 1994, 3, 14-19.	2.2	0
142	Breast Cancer in Older Women. Journal of the American Geriatrics Society, 2001, 49, 1004-1005.	2.6	0
143	P343 CARIATIDE trial: the impact of educational materials (EM) on patients' compliance with adjuvant aromatase inhibitor (AI) therapy and quality of life (QoL). Breast, 2011, 20, S83-S84.	2.2	0
144	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer. Obstetrical and Gynecological Survey, 2012, 67, 415-416.	0.4	0

#	Article	IF	CITATIONS
145	Conference Scene: Breast cancer management: towards optimum diagnostic and therapeutic methods. Breast Cancer Management, 2013, 2, 459-462.	0.2	0
146	The Effect of Physician'S Characteristics on Adjuvant Chemotherapy (Ct) Decisions for Early Stage Hr + , Her2– Breast Cancer (Bc) Patients (Pts). Annals of Oncology, 2014, 25, iv88.	1.2	0
147	157. Comparing medical oncologists' and surgeons' treatment recommendations in early stage HR+, HER2– breast cancer (BC) patients (pts): A subanalysis of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey. European Journal of Surgical Oncology, 2014, 40, S69.	1.0	0
148	Molecular Profiling of Breast Cancer and DCIS. , 2018, , 89-101.		0
149	MCQ Self-Test. , 2018, , 715-718.		0
150	Current Concept of Sentinel Lymph Node Biopsy. , 2021, , 499-507.		0
151	Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study. Npj Breast Cancer, 2021, 7, 90.	5.2	0
152	Abstract P1-10-03: CARIATIDE: The Impact of Educational Materials and Demographic Characteristics on Compliance with Adjuvant Aromatase Inhibitor Treatment. , 2010, , .		0
153	Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the TEAM pathology study Journal of Clinical Oncology, 2012, 30, 516-516.	1.6	0
154	A pilot laboratory study comparing the 21-gene assay and PAM50-ROR Journal of Clinical Oncology, 2014, 32, 11003-11003.	1.6	0
155	Abstract P4-11-05: Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study. , 2015, , .		0
156	Abstract P6-08-06: The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early stage hormone receptor-positive (HR+), HER2– breast cancer (BC) patients for whom multigene assays may be valuable. , 2015, , .		0
157	Effect of mutant TP53 genotypes on the outcome of breast cancer (BC) patients in different clinical tumor subtypes Journal of Clinical Oncology, 2015, 33, 11041-11041.	1.6	0
158	Abstract P4-03-07: Analysis of hereditary cancer syndromes by using a panel of genes: Novel and multiple pathogenic mutations. , 2019, , .		0
159	Educational and Training Harmonization in Breast Care. , 2019, , 64-70.		Ο